Worldwide Business with kathy ireland®
March 12, 2021
No Comments
A clear mask in oncology care addresses a communication need many treatment teams overlook: hearing loss caused by the cancer treatment itself, not just the hearing status a patient walked in with. Platinum-based chemotherapy drugs are well documented to cause ototoxicity, meaning oncology patients frequently develop hearing changes during the exact period when they need to understand complex information about their diagnosis, treatment plan, and side effects most clearly. A transparent mask supports that communication need independent of whether a patient was Deaf or hard of hearing before treatment began.
Safe’N’Clear, Inc. supplies FDA cleared transparent masks through The Communicator™ Procedural Face Mask, giving oncology teams a way to maintain infection-control standards in an immunocompromised patient population without losing the visible communication those same patients often need more than most. The full Safe’N’Clear healthcare PPE line covers the filtration levels an oncology unit typically needs, from infusion suites to surgical settings.
Platinum-based chemotherapy drugs, including cisplatin and carboplatin, are widely used to treat testicular, ovarian, cervical, lung, and head and neck cancers, among others. The American Cancer Society’s guidance on hearing problems in cancer survivors identifies platinum-based chemo as a leading cause of treatment-related hearing loss, describing the condition as ototoxicity, meaning damage to the nerves and inner-ear structures responsible for hearing and balance.
A peer-reviewed review of cisplatin-induced ototoxicity estimates that ototoxicity affects roughly 36 percent of adult cancer patients and 40 to 60 percent of pediatric patients treated with cisplatin, with damage that is cumulative across treatment cycles and often permanent. This hearing loss typically begins in the high-frequency range, which can affect a patient’s ability to follow consonant sounds and speech clarity well before the change becomes noticeable in everyday conversation.
Radiation therapy directed at the head, ear, or brain carries a similar risk, and certain non-chemotherapy medications used to manage cancer-related infections can contribute to hearing changes as well. Because these effects accumulate with dose and treatment duration, a patient early in a treatment course may have no hearing changes at all, while the same patient several cycles later may be managing a meaningful hearing loss without a formal diagnosis or hearing aid in place yet, since routine hearing testing is not universally built into standard oncology follow-up care.
An oncology patient experiencing early, high-frequency hearing loss may not yet recognize the change themselves, making a masked conversation harder to follow without an obvious explanation for why. This timing creates a particular risk: the same treatment cycle causing hearing changes often includes some of the most complex conversations in a patient’s care, from explaining scan results to discussing a change in treatment plan to reviewing new medication instructions.
Older adults make up a large share of the oncology patient population, and age-related hearing loss frequently compounds with treatment-related ototoxicity, particularly for patients receiving multiple cycles of platinum-based chemotherapy over months of treatment. A patient managing both conditions at once has even less margin for a muffled, masked conversation to go correctly the first time. Family members and caregivers accompanying a patient to appointments often serve as an informal check on whether information was understood correctly, but that safety net does not cover every conversation a patient has directly with a nurse or physician, particularly during an infusion visit when a caregiver may step out of the room.
Patients undergoing cancer treatment also report elevated anxiety and emotional distress around appointments, a state that can further reduce how well someone processes spoken information even without any hearing change present. A visible, readable face gives an anxious patient one more anchor for understanding difficult information, on top of whatever hearing-related benefit a transparent mask provides.
Infusion centers involve extended time between a patient and nursing staff, often over several hours per session, giving nurses many opportunities to explain side effects, answer questions, and check in on how a patient is tolerating treatment. A transparent mask keeps that ongoing conversation accessible throughout a long infusion, rather than only at the start and end of a visit. Oncology consultations covering diagnosis, staging, and treatment options involve dense, unfamiliar medical information that patients need to process accurately, often while also managing the emotional weight of a cancer diagnosis, making visible communication more valuable rather than less during these conversations.
Palliative and supportive care conversations carry similar weight, often covering symptom management, goals of care, and end-of-life planning discussions where precision and emotional clarity both matter. A patient or family member navigating one of these conversations benefits from seeing a provider’s face throughout, both for the informational content and for the human connection that a visible expression of empathy provides during an especially difficult moment.
Surgical oncology settings carry the same infection-control demands as any operating room, and ASTM Level 3 gives surgical oncology teams the filtration performance those procedures require without sacrificing the pre- and post-operative communication that shapes a patient’s understanding of their own care. Routine oncology visits, consultations, and infusion appointments are typically well served by ASTM Level 1, covering the majority of day-to-day oncology encounters.
Oncology care shares a structural similarity with other treatment settings involving frequent, recurring visits over an extended period. A closer look at clear masks in dialysis care covers a comparable setting where patients see the same care team repeatedly over months or years, and where visible communication compounds in value across that many encounters rather than mattering only once. Both settings also involve patients managing a serious diagnosis alongside treatment logistics, medication schedules, and side-effect monitoring, all of which depend on clear, repeated communication between patient and care team over time rather than a single well-explained visit.
An oncology unit standardizing on transparent masks across infusion nurses, physicians, and support staff creates a consistent communication experience for a patient returning for cycle after cycle of treatment, rather than a hit-or-miss experience that depends on which individual staff member happens to be assigned that day.
Does chemotherapy actually cause hearing loss? Yes. Platinum-based chemotherapy drugs, including cisplatin and carboplatin, are well documented to cause ototoxicity, damaging the inner ear and auditory nerves in a substantial share of adult and pediatric cancer patients.
Why would a hearing patient need a transparent mask during cancer treatment? Chemotherapy-induced hearing changes can develop gradually during treatment, often starting in the high-frequency range before a patient notices the change, meaning a patient with no prior hearing loss may still benefit from visible communication partway through treatment.
What ASTM level is appropriate for oncology settings? ASTM Level 1 covers most routine oncology visits, consultations, and infusion appointments, while surgical oncology procedures call for ASTM Level 3 protection.
Hearing changes caused by treatment itself make transparent masks relevant to oncology care in a way that goes beyond a patient’s hearing status at diagnosis. The Communicator™ Mask gives oncology teams an FDA cleared, ADA effective way to keep communication clear across consultations, infusion visits, and surgical procedures alike. Visit the Safe’N’Clear purchase guide to equip your oncology unit with the right level of protection for every patient encounter.
